Investigational drug · Phase 3
QLS4131
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "QLS4131"
First trial start
2026
Jun 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS4131", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Plasma Cell Neoplasms
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS4131" as an intervention, largest first.
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07933432 · 300 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 14, 2029
Drug: QLS4131; Pomalidomide Capsules and 3 more · For: Relapsed or Refractory Multiple Myeloma
- QLS4131 Combination Therapy in Malignant Plasma Cell NeoplasmsNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07560449 · 162 participants (planned) · Start Jun 2026 · Primary completion Jun 2028
Drug: QLS4131; QL2109 and 3 more · For: Malignant Plasma Cell Neoplasms
Qilu Pharmaceutical Co., Ltd.Industry
NCT07001839 · 108 participants (planned) · Start Jun 2025 · Primary completion Dec 2026
Drug: QLS4131 for Injection. · For: Systemic Lupus Erythematosus
Qilu Pharmaceutical Co., Ltd.Industry
NCT06500507 · 90 participants (planned) · Start Aug 30, 2024 · Primary completion Mar 31, 2026
Drug: QLS4131 Injection · For: Relapsed or Refractory Multiple Myeloma
Sites: Tianjin, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07903636 · 55 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2027
Drug: QLS4131 · For: Multiple Myeloma (MM)
Sites: Tianjin, China
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07751471 · 20 participants (planned) · Start Jul 20, 2026 · Primary completion Dec 31, 2027
Drug: QLS4131 · For: AL Amyloidosis
Sites: Tianjin, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07903623 · 15 participants (planned) · Start Oct 25, 2026 · Primary completion Dec 30, 2029
Drug: QLS4131; Isatuximab · For: Primary Plasma Cell Leukemia
Sites: Tianjin, China
- QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II StudyNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07921615 · 10 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 9, 2027
Drug: QLS4131 combined with Isa-V-CHOP · For: Plasmablastic Lymphoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.